“Doctor, if it were you, which would you choose?”: Navigating personal preference questions in anti‐amyloid immunotherapy selection

The approval of lecanemab and donanemab represents a watershed moment in Alzheimer Disease (AD) treatment, yet clinicians face a novel challenge: guiding patients through treatment selection when head‐to‐head comparative data are absent. When confronted with the question “What would you do if you were me?”, clinical providers must balance evidence‐based medicine with the therapeutic alliance. This perspective examines the ethical, practical, and relational dimensions of responding to personal preference queries in the context of anti‐amyloid immunotherapy selection, offering a framework for authentic engagement that honors both professional boundaries and patient‐centered care.